Corneal Dystrophy clinical trials

Explore recruiting corneal dystrophy clinical trials.

Recruiting corneal dystrophy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Corneal Dystrophy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy

Denmark, Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared with Vehicle in Subjects with Fuchs Endothelial Corneal Dystrophy (FECD) - PHANTOM Study

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12 Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy

Germany, Denmark, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Corneal Dystrophy trials by city

Corneal Dystrophy in Toronto Corneal Dystrophy in Vancouver Corneal Dystrophy in Montreal Corneal Dystrophy in Calgary Corneal Dystrophy in Edmonton Corneal Dystrophy in Ottawa Corneal Dystrophy in Winnipeg Corneal Dystrophy in Quebec City Corneal Dystrophy in Hamilton Corneal Dystrophy in Kitchener Corneal Dystrophy in London Corneal Dystrophy in Halifax Corneal Dystrophy in New York Corneal Dystrophy in Los Angeles Corneal Dystrophy in Chicago Corneal Dystrophy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease